165 related articles for article (PubMed ID: 10569136)
21. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
Corradini P; Ladetto M; Pileri A; Tarella C
Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
23. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
Batlle M; Ribera JM; Oriol A; Pastor C; Mate JL; Fernández-Avilés F; Flores A; Millá F; Feliu E
Leuk Lymphoma; 2005 Oct; 46(10):1471-6. PubMed ID: 16194893
[TBL] [Abstract][Full Text] [Related]
25. Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma.
Hoogeveen-Westerveld M; Hupkes PE; Doekharan D; Dorssers LC; van't Veer MB; van Belzen N
Leukemia; 1998 Nov; 12(11):1810-6. PubMed ID: 9823958
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO.
d'Amore F; Johansen P; Houmand A; Weisenburger DD; Mortensen LS
Blood; 1996 Feb; 87(3):1045-55. PubMed ID: 8562929
[TBL] [Abstract][Full Text] [Related]
27. Treatment of T-cell non-Hodgkin's lymphoma.
Evens AM; Gartenhaus RB
Curr Treat Options Oncol; 2004 Aug; 5(4):289-303. PubMed ID: 15233906
[TBL] [Abstract][Full Text] [Related]
28. Non-Hodgkin's lymphoma.
Smith MR
Curr Probl Cancer; 1996; 20(1):6-77. PubMed ID: 8919170
[TBL] [Abstract][Full Text] [Related]
29. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers in childhood non-Hodgkin's lymphomas.
Dokmanovic L
Biomark Med; 2013 Oct; 7(5):791-801. PubMed ID: 24044571
[TBL] [Abstract][Full Text] [Related]
31. Non-Hodgkin's lymphoma in the older person: a review.
Ballester OF; Moscinski L; Spiers A; Balducci L
J Am Geriatr Soc; 1993 Nov; 41(11):1245-54. PubMed ID: 7693787
[TBL] [Abstract][Full Text] [Related]
32. Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases.
Zarate-Osorno A; Medeiros LJ; Kingma DW; Longo DL; Jaffe ES
Am J Surg Pathol; 1993 Feb; 17(2):123-32. PubMed ID: 8422110
[TBL] [Abstract][Full Text] [Related]
33. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting.
Corradini P; Astolfi M; Cherasco C; Ladetto M; Voena C; Caracciolo D; Pileri A; Tarella C
Blood; 1997 Jan; 89(2):724-31. PubMed ID: 9002976
[TBL] [Abstract][Full Text] [Related]
34. Clinical and prognostic analysis of 125 cases of non-Hodgkin's lymphoma.
Liu L; Zhang M; Zou P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):547-50. PubMed ID: 18549626
[TBL] [Abstract][Full Text] [Related]
35. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
Møller MB; Nielsen O; Pedersen NT
Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
[TBL] [Abstract][Full Text] [Related]
36. Prognostic parameters in low-grade non-Hodgkin's lymphomas.
Zemunik T; Vucković J; Forenpoher G; Knezević N; Stula N; Dubravcić M; Ribicić I; Rozga A
Neoplasma; 1997; 44(1):13-7. PubMed ID: 9201275
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease.
Kingma DW; Medeiros LJ; Barletta J; Raffeld M; Mann RB; Ambinder RF; Jaffe ES
Am J Surg Pathol; 1994 Jan; 18(1):48-61. PubMed ID: 8279628
[TBL] [Abstract][Full Text] [Related]
38. Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma.
Demir I; Akan OY; Bilgir F; Yilmaz I; Bozkaya G; Bilgir O
Ir J Med Sci; 2024 Jun; 193(3):1201-1207. PubMed ID: 38270775
[TBL] [Abstract][Full Text] [Related]
39. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
[TBL] [Abstract][Full Text] [Related]
40. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands.
Maartense E; Hermans J; Kluin-Nelemans JC; Kluin PM; Van Deijk WA; Snijder S; Wijermans PW; Noordijk EM
Ann Oncol; 1998 Nov; 9(11):1219-27. PubMed ID: 9862053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
